Oligomerix
Headquarters: 1300 Morris Park Ave, Bronx, NY 10461
Founded: Based on NYU research
Focus: Tau protein aggregation inhibitors, [Alzheimer's disease](/diseases/alzheimers-disease), neurodegenerative diseases
Stage: Clinical-stage biotechnology company
Website: [oligomerix.com](https://www.oligomerix.com)
Overview
flowchart TD
companies_oligomerix["Oligomerix, Inc."]
style companies_oligomerix fill:#4fc3f7,stroke:#333,color:#000
companies_oligomerix_0["Company Background"]
companies_oligomerix -->|"includes"| companies_oligomerix_0
style companies_oligomerix_0 fill:#81c784,stroke:#333,color:#000
companies_oligomerix_1["Scientific Heritage"]
companies_oligomerix -->|"includes"| companies_oligomerix_1
style companies_oligomerix_1 fill:#ef5350,stroke:#333,color:#000
companies_oligomerix_2["Clinical Pipeline"]
companies_oligomerix -->|"includes"| companies_oligomerix_2
style companies_oligomerix_2 fill:#ffd54f,stroke:#333,color:#000
companies_oligomerix_3["OLX-07010 Lead Program"]
companies_oligomerix -->|"includes"| companies_oligomerix_3
style companies_oligomerix_3 fill:#ce93d8,stroke:#333,color:#000
companies_oligomerix_4["Therapeutic Areas"]
companies_oligomerix -->|"includes"| companies_oligomerix_4
style companies_oligomerix_4 fill:#4fc3f7,stroke:#333,color:#000
companies_oligomerix_5["Pipeline Overview"]
companies_oligomerix -->|"includes"| companies_oligomerix_5
style companies_oligomerix_5 fill:#81c784,stroke:#333,color:#000
...Oligomerix
Headquarters: 1300 Morris Park Ave, Bronx, NY 10461
Founded: Based on NYU research
Focus: Tau protein aggregation inhibitors, [Alzheimer's disease](/diseases/alzheimers-disease), neurodegenerative diseases
Stage: Clinical-stage biotechnology company
Website: [oligomerix.com](https://www.oligomerix.com)
Overview
Mermaid diagram (expand to render)
Oligomerix is a clinical-stage biotechnology company focused on developing small molecule inhibitors targeting tau protein aggregation for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company was founded based on research from New York University and operates from New York["@oligomerix2026"].
The company's name reflects its scientific focus—targeting protein oligomers, which are toxic aggregated forms of proteins that drive neurodegeneration. Unlike approaches that focus on amyloid plaques, Oligomerix targets the tau protein oligomers that form inside [neurons](/entities/neurons) and propagate between brain regions.
With over 16 years of tau research, Oligomerix has established an innovative upstream approach to treating tauopathies through targeting the root cause of tau pathology["@oligomerix2026a"]. This approach addresses the fundamental mechanism of tau propagation, offering the potential for disease modification rather than just symptomatic treatment.
Company Background
Oligomerix emerged from academic research conducted at New York University, one of the world's leading centers for tau biology research. The company's founding scientists brought decades of experience in protein aggregation mechanisms and drug discovery for neurodegenerative diseases.
Operating from New York provides Oligomerix with access to:
- World-class research institutions (NYU, Columbia, Rockefeller)
- Experienced drug development talent from major pharmaceutical companies
- Strong pharmaceutical industry presence
- NIH-funded research programs
- Clinical trial infrastructure
Scientific Heritage
The company's origins trace to groundbreaking research on tau protein aggregation conducted at NYU's School of Medicine. This research established key mechanistic insights into how tau transitions from a normal, functional protein to toxic oligomeric and fibrillar species.
Clinical Pipeline
OLX-07010 (Lead Program)
OLX-07010 is Oligomerix's lead small molecule drug candidate—a tau self-association inhibitor. This first-in-class therapeutic represents a novel approach to treating tauopathies by directly targeting the oligomerization process that drives pathology propagation[@olx2026].
| Attribute | Value |
|-----------|-------|
| Program | OLX-07010 |
| Mechanism | Tau Self-Association Inhibitor |
| Target | Tau protein oligomers |
| Indication | Alzheimer's disease, PSP |
| Development Stage | Phase 1a clinical trials (first-in-human) |
Therapeutic Areas
- Alzheimer's Disease: The lead indication, representing the most common tauopathy
- Progressive Supranuclear Palsy (PSP): A pure tauopathy providing a well-defined clinical population
- Rare Tauopathies: Additional indications under development including corticobasal degeneration
Pipeline Overview
| Program | Indication | Target | Development Status |
|---------|------------|--------|-------------------|
| OLX-07010 | Alzheimer's Disease | Tau oligomers | Phase 1a (first-in-human) |
| OLX-07010 | Progressive Supranuclear Palsy | Tau oligomers | Preclinical |
| Additional programs | Other tauopathies | Tau | Research/Discovery |
Science and Technology
Tau Biology and Pathology
The tau protein is a microtubule-associated protein primarily expressed in neurons. Under normal conditions, tau stabilizes microtubules, which are essential for cellular transport and neuronal integrity. However, in disease states, tau undergoes pathological transformations that contribute to neurodegeneration[@wang2016].
Normal Tau Function
- Microtubule stabilization: Tau binds to microtubules, promoting their polymerization and stability
- Axonal transport: Facilitates intracellular transport along microtubules
- Neuronal development: Important for neuronal polarization and connectivity
- Synaptic function: Modulates synaptic plasticity and function
In Alzheimer's disease and related tauopathies, the tau protein undergoes pathological changes:
Hyperphosphorylation: Abnormal phosphorylation by kinases including [GSK-3β](/entities/gsk3-beta) and [CDK5](/proteins/cdk5) causes tau to detach from microtubules
Oligomer formation: Hyperphosphorylated tau forms soluble toxic oligomers - the most damaging species
Fibril aggregation: Oligomers aggregate into insoluble neurofibrillary tangles (NFTs)
Spread throughout brain: Pathological tau propagates via neural networks, spreading pathology between brain regionsThe Tau Oligomer Hypothesis
The "tau oligomer" hypothesis, which forms the scientific foundation for Oligomerix's approach, suggests that soluble tau oligomers are the most toxic species in tauopathies[@tau2020]. This hypothesis has gained significant support from research demonstrating that:
- Oligomers are toxic: Soluble oligomers are more toxic to neurons than insoluble tangles
- Oligomers spread: Tau oligomers propagate between neurons, spreading pathology
- Oligomers appear early: Oligomers appear before tangle formation
- Oligomers correlate with symptoms: Tau oligomer levels correlate better with cognitive decline than tangle burden
The toxic effects of tau oligomers include:
- Synaptic dysfunction and loss: Oligomers disrupt synaptic plasticity and cause synapse elimination
- Neuronal death: Direct toxicity leads to neuronal loss
- Spread of pathology: Propagation via neural networks spreads tau pathology
- Microglial activation: Oligomers trigger inflammatory responses
Therapeutic Approach
Oligomerix develops small molecules that target tau oligomers through multiple mechanisms:
Inhibit tau oligomer formation: Prevent the initial aggregation of tau monomers into oligomers
Disassemble existing oligomers: Break down toxic oligomeric species
Block tau propagation: Prevent spread between neurons
Reduce neurofibrillary tangles: Ultimately decrease insoluble tangle burdenOligomerix's drug discovery platform includes:
- High-throughput screening: Identification of initial hit compounds
- Structure-activity relationship (SAR) optimization: Systematic improvement of hit compounds
- In vitro assays: Tau aggregation, oligomerization, and cell-based assays
- Animal models: Transgenic tauopathy mouse models for in vivo validation
- Computational chemistry: Structure-based drug design
Differentiating Factors
Oligomerix's approach offers several key differentiators:
- Intracellular targeting: Small molecules reach intracellular tau where oligomers form
- Oligomer specificity: Targets toxic oligomers specifically, not just total tau
- Oral bioavailability: Small molecules suitable for chronic daily dosing
- Combination potential: Works synergistically with amyloid-targeting approaches
- Upstream intervention: Targets root cause of tau propagation
Clinical Development Strategy
Phase 1a Trial Design
The Phase 1a trial of OLX-07010 is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. This first-in-human study establishes the foundation for subsequent trials in patients.
Key objectives:
- Single ascending dose (SAD) safety assessment
- Multiple ascending dose (MAD) evaluation
- Pharmacokinetic profiling
- Food effect study
- Biomarker development
Patient Populations
Oligomerix is developing OLX-07010 for multiple patient populations:
Alzheimer's Disease (AD)
- Most common neurodegenerative disease
- Significant unmet need for disease-modifying therapies
- [Tau](/proteins/tau) pathology strongly correlates with cognitive decline
Progressive Supranuclear Palsy (PSP)
- Pure tauopathy with defined pathology
- Faster disease progression than AD
- Well-characterized patient population
Biomarker Strategy
Oligomerix is developing biomarkers to support clinical development:
- Tau PET imaging: Visualization of tau pathology burden
- CSF biomarkers: Tau and phospho-tau levels
- Blood-based biomarkers: Emerging fluid biomarkers for tau
- Cognitive measures: Standardized cognitive assessments
Competitive Landscape
Oligomerix competes in the tau aggregation inhibitor and anti-tau therapy space:
| Company | Drug | Approach | Target | Status |
|---------|------|----------|--------|--------|
| Oligomerix | OLX-07010 | Small molecule | Tau oligomers | Phase 1a |
| Axon Neuroscience | AADvac1 | Vaccine | Tau (phospho) | Phase 2 |
| Biogen/IONIS | BIIB080 | Antisense oligo | Tau mRNA | Phase 1/2 |
| Eli Lilly | Semorinemab | Antibody | Tau antibody | Phase 2 (failed) |
| Roche/Genentech | Gosuranemab | Antibody | Tau antibody | Phase 2/3 |
| ABBV-916 | ABBV-916 | Antibody | Tau antibody | Phase 1 |
Competitive Advantages
Oligomerix believes its small molecule approach offers advantages:
- Oral dosing vs. intravenous antibodies
- Intracellular access to tau oligomers
- Potential for combination with other approaches
- Disease-modifying mechanism addressing tau propagation
Oligomerix maintains a robust discovery platform:
- In vitro assays: Tau aggregation, oligomerization, and cell-based assays
- Cellular models: Induced pluripotent stem cell (iPSC)-derived neurons
- Animal models: Transgenic tauopathy mouse models (P301S, rTg4510)
- Computational chemistry: Structure-based drug design and molecular modeling
- Biomarker development: Patient selection and treatment response markers
- Pharmacology: Dose-response and mechanism-of-action studies
Relevance to Neurodegeneration
Tau pathology is central to several neurodegenerative diseases, making Oligomerix's approach broadly applicable:
Alzheimer's Disease
- Neurofibrillary tangles strongly correlate with cognitive decline
- [Tau](/proteins/tau) spread predicts disease progression patterns
- [Tau](/proteins/tau) PET imaging enables disease staging
- [Tau](/proteins/tau) is now recognized as a key therapeutic target
Other Tauopathies
- Progressive supranuclear palsy: Pure tauopathy with 4R tau pathology
- Corticobasal degeneration: Mixed 3R/4R tau pathology
- Frontotemporal dementia: Various tau subtypes
- Chronic traumatic encephalopathy: Tau pathology from repetitive trauma
Disease Progression Patterns
Tau pathology follows predictable patterns in Alzheimer's, known as the Braak staging system:
Braak Stage I-II: [Entorhinal cortex](/brain-regions/entorhinal-cortex) (early, may be preclinical)
Braak Stage III-IV: [Hippocampus](/brain-regions/hippocampus) and limbic regions (early-mid disease)
Braak Stage V-VI: Neocortex (late disease)Understanding this progression informs therapeutic development and patient selection.
Funding and Partnerships
Oligomerix has advanced through multiple funding sources:
- Venture capital: Series funding from biotech-focused investors
- NIH grants: Grant funding for rare disease research
- Strategic partnerships: Collaborations with larger pharmaceutical companies
- Foundation support: Tau research foundations and disease organizations
Academic Collaborations
Oligomerix maintains active collaborations with:
- New York University (founding institution)
- Other leading tau research centers
- Clinical trial networks
Future Directions
Oligomerix's development priorities include:
Complete Phase 1 trials: Establish safety and dosing for Phase 2
Initiate Phase 2 trials: Proof-of-concept in Alzheimer's and PSP
Expand pipeline: Advance additional tau targets
Develop biomarkers: Enable patient selection and monitoringRelated Pages
- [Tau Protein](/proteins/tau)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Tauopathies](/entities/tauopathies)
- [Protein Aggregation](/entities/protein-aggregation)
- [Neurodegeneration](/entities/neurodegeneration)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Corticobasal Degeneration](/diseases/corticobasal-degeneration)
- [Neurofibrillary Tangles](/entities/neurofibrillary-tangles)
- [Tau Propagation](/entities/tau-propagation)
External Links
- [Oligomerix Website](https://www.oligomerix.com)
- [ClinicalTrials.gov](https://clinicaltrials.gov)
- [Alzheimer's Association](https://www.alz.org)
- [CurePSP Foundation](https://www.curepsp.org)
References
Oligomerix, Company Overview (2026)
Oligomerix Pipeline, Clinical Development Programs (2026)
Unknown, OLX-07010 Clinical Trial Information (2026)
[Wang Y, Mandelkow E, Tau in physiology and pathology (2016)](https://pubmed.ncbi.nlm.nih.gov/26751491/)
Unknown, Tau Oligomer Hypothesis (2020)